Dimensional Fund Advisors LP Buys 28,074 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Dimensional Fund Advisors LP boosted its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 283.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,981 shares of the company's stock after buying an additional 28,074 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.08% of Tyra Biosciences worth $528,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TYRA. China Universal Asset Management Co. Ltd. acquired a new position in Tyra Biosciences during the 4th quarter worth about $149,000. Rhumbline Advisers lifted its holdings in Tyra Biosciences by 4.1% during the 4th quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after buying an additional 1,027 shares during the period. Bank of New York Mellon Corp lifted its holdings in Tyra Biosciences by 5.2% during the 4th quarter. Bank of New York Mellon Corp now owns 45,007 shares of the company's stock worth $626,000 after buying an additional 2,221 shares during the period. US Bancorp DE acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at about $50,000. Finally, Alta Partners Management Company L.P. acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at about $56,716,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TYRA. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday, March 31st. Piper Sandler began coverage on Tyra Biosciences in a research note on Wednesday. They issued an "overweight" rating and a $33.00 price objective on the stock. Finally, Wedbush reissued an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $30.83.

Tyra Biosciences Trading Down 1.7%

Tyra Biosciences stock traded down $0.17 during midday trading on Thursday, reaching $9.59. The stock had a trading volume of 153,118 shares, compared to its average volume of 263,347. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $29.60. The company has a market capitalization of $509.13 million, a P/E ratio of -5.96 and a beta of 1.17. The company has a fifty day moving average price of $9.46 and a two-hundred day moving average price of $12.67.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.